# Christine Lebrun-frenay

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 170 papers | 9,174 citations | 44069 48 h-index | 46799 89 g-index |
| 231 all docs | 231 docs citations | 231 times ranked | 9731 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360. | 21.4 | 1,213 |
| 2 | Natural History of Multiple Sclerosis with Childhood Onset. New England Journal of Medicine, 2007, 356, 2603-2613. | 27.0 | 631 |
| 3 | Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. Neurology, 2018, 90, e1858-e1869. | 1.1 | 401 |
| 4 | Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurology, 2020, 77, 1079. | 9.0 | 357 |
| 5 | Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event. PLoS ONE, 2014, 9, e90509. | 2.5 | 254 |
| 6 | MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Multiple Sclerosis Journal, 2016, 22, 1719-1731. | 3.0 | 249 |
| 7 | Association Between Clinical Conversion to Multiple Sclerosis in Radiologically Isolated Syndrome and Magnetic Resonance Imaging, Cerebrospinal Fluid, and Visual Evoked Potential. Archives of Neurology, 2009, 66, 841. | 4.5 | 191 |
| 8 | High doses of biotin in chronic progressive multiple sclerosis: A pilot study. Multiple Sclerosis and Related Disorders, 2015, 4, 159-169. | 2.0 | 191 |
| 9 | Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Multiple Sclerosis Journal, 2007, 13, 256-259. | 3.0 | 190 |
| 10 | Idiopathic acute transverse myelitis: Application of the recent diagnostic criteria. Neurology, 2005, 65, 1950-1953. | 1.1 | 149 |
| 11 | Acute Fulminant Demyelinating Disease. Archives of Neurology, 2007, 64, 1426. | 4.5 | 148 |
| 12 | Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet, The, 2015, 386, 974-981. | 13.7 | 144 |
| 13 | <scp>I</scp> -Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology, 2013, 81, 865-871. | 1.1 | 140 |
| 14 | Switching From Natalizumab to Fingolimod in Multiple Sclerosis. JAMA Neurology, 2014, 71, 436. | 9.0 | 133 |
| 15 | Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 521-525. | 3.0 | 131 |
| 16 | Primary <scp>P</scp>rogressive <scp>M</scp>ultiple <scp>S</scp>clerosis <scp>E</scp>volving <scp>F</scp>rom <scp>R</scp>adiologically <scp>I</scp>solated <scp>S</scp>yndrome. Annals of Neurology, 2016, 79, 288-294. | 5.3 | 130 |
| 17 | Interferon-Î² treatment in patients with childhood-onset multiple sclerosis. Journal of Pediatrics, 2001, 139, 443-446. | 1.8 | 116 |
| 18 | Cognitive function in radiologically isolated syndrome. Multiple Sclerosis Journal, 2010, 16, 919-925. | 3.0 | 116 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 195-198. | 1.9 | 112 |
| 20 | Long-term safety and efficacy of teriflunomide. Neurology, 2016, 86, 920-930. | 1.1 | 108 |
| 21 | Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. European Journal of Endocrinology, 2017, 176, 769-777. | 3.7 | 107 |
| 22 | Nonconvulsive status epilepticus of frontal origin. Neurology, 1999, 52, 1174-1174. | 1.1 | 107 |
| 23 | Increased risk of multiple sclerosis relapse after in vitro fertilisation. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 796-802. | 1.9 | 102 |
| 24 | Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 399-405. | 3.0 | 101 |
| 25 | Nitroso-ureaâ€“cisplatin-based chemotherapy associated with valproate: Increase of haematologic toxicity. Annals of Oncology, 2001, 12, 217-220. | 1.2 | 100 |
| 26 | Successful treatment of refractory generalized myasthenia gravis with rituximab. European Journal of Neurology, 2009, 16, 246-250. | 3.3 | 100 |
| 27 | Cognitive Functions in Neuromyelitis Optica. Archives of Neurology, 2008, 65, 84-8. | 4.5 | 98 |
| 28 | Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain, 2011, 134, 693-703. | 7.6 | 96 |
| 29 | Radiologically Isolated Syndrome: <scp>10â€Year</scp> Risk Estimate of a Clinical Event. Annals of Neurology, 2020, 88, 407-417. | 5.3 | 95 |
| 30 | Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. Journal of Neurology, 2015, 262, 2329-2335. | 3.6 | 86 |
| 31 | Long-term outcome of oligodendrogliomas. Neurology, 2004, 62, 1783-1787. | 1.1 | 80 |
| 32 | Comparative efficacy of fingolimod vs natalizumab. Neurology, 2016, 86, 771-778. | 1.1 | 71 |
| 33 | Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs. CNS Drugs, 2018, 32, 939-949. | 5.9 | 69 |
| 34 | Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. Journal of Autoimmunity, 2017, 79, 84-90. | 6.5 | 67 |
| 35 | Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. Journal of the Neurological Sciences, 2004, 218, 73-77. | 0.6 | 63 |
| 36 | Rituximab in refractory and nonâ€refractory myasthenia: A retrospective multicenter study. Muscle and Nerve, 2012, 46, 687-691. | 2.2 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Acute aphasia in multiple sclerosis. Neurology, 2004, 62, 974-977. | 1.1 | 61 |
| 38 | Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. European Journal of Neurology, 2007, 14, 391-398. | 3.3 | 58 |
| 39 | Adult-onset genetic leukoencephalopathies: A MRI pattern-based approach in a comprehensive study of 154 patients. Brain, 2015, 138, 284-292. | 7.6 | 58 |
| 40 | Monitoring CD27 + memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study. Journal of the Neurological Sciences, 2017, 373, 335-338. | 0.6 | 58 |
| 41 | More severe disability of North Africans vs Europeans with multiple sclerosis in France. Neurology, 2007, 68, 29-32. | 1.1 | 57 |
| 42 | Cervical spinal cord atrophy. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e435. | 6.0 | 57 |
| 43 | Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?. Aids, 2014, 28, 493-501. | 2.2 | 55 |
| 44 | International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1809-1818. | 3.0 | 55 |
| 45 | A Benign Form of Neuromyelitis Optica. Archives of Neurology, 2011, 68, 918. | 4.5 | 54 |
| 46 | Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. Multiple Sclerosis Journal, 2012, 18, 1297-1302. | 3.0 | 53 |
| 47 | Cancer and multiple sclerosis in the era of disease-modifying treatments. Journal of Neurology, 2011, 258, 1304-1311. | 3.6 | 52 |
| 48 | CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1027-1038. | 1.9 | 51 |
| 49 | Characteristics in limbic encephalitis with antiâ€“adenylate kinase 5 autoantibodies. Neurology, 2017, 88, 514-524. | 1.1 | 49 |
| 50 | Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. PLoS ONE, 2015, 10, e0132033. | 2.5 | 48 |
| 51 | First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. European Journal of Neurology, 2005, 12, 685-690. | 3.3 | 45 |
| 52 | Comparison of Simoa<sup>TM</sup> and Ella<sup>TM</sup> to assess serum neurofilamentâ€light chain in multiple sclerosis. Annals of Clinical and Translational Neurology, 2021, 8, 1141-1150. | 3.7 | 45 |
| 53 | Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society. Multiple Sclerosis and Related Disorders, 2019, 31, 173-188. | 2.0 | 44 |
| 54 | Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Multiple Sclerosis Journal, 2010, 16, 87-92. | 3.0 | 43 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis. Journal of Neuroimmunology, 2016, 298, 79-81. | 2.3 | 42 |
| 56 | Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. Journal of the Neurological Sciences, 2016, 363, 69-76. | 0.6 | 42 |
| 57 | Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Multiple Sclerosis Journal, 2006, 12, 321-324. | 3.0 | 41 |
| 58 | Radiologically isolated syndrome in children. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e395. | 6.0 | 41 |
| 59 | Immunoglobulin G4-related hypertrophic pachymeningitis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e568. | 6.0 | 41 |
| 60 | Up-front chemotherapy with fotemustine (F)/cisplatin (CDDP)/etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas. European Journal of Cancer, 2000, 36, 1026-1031. | 2.8 | 38 |
| 61 | Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology, 2019, 93, e635-e646. | 1.1 | 36 |
| 62 | Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. JAMA Neurology, 2020, 77, 94. | 9.0 | 36 |
| 63 | Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. JAMA Network Open, 2021, 4, e2128271. | 5.9 | 32 |
| 64 | Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders. Neurology and Therapy, 2018, 7, 373-383. | 3.2 | 31 |
| 65 | Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. Journal of Neuroinflammation, 2022, 19, 62. | 7.2 | 30 |
| 66 | Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study. Journal of NeuroVirology, 2013, 19, 376-382. | 2.1 | 29 |
| 67 | Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. Journal of Neurology, 2018, 265, 2251-2259. | 3.6 | 29 |
| 68 | Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome. Multiple Sclerosis Journal, 2019, 25, 669-677. | 3.0 | 28 |
| 69 | MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study. CNS Drugs, 2018, 32, 661-672. | 5.9 | 26 |
| 70 | Imaging spectrum of Bingâ€“Neel syndrome: how can a radiologist recognise this rare neurological complication of WaldenstrÃ¶mâ€™s macroglobulinemia?. European Radiology, 2019, 29, 102-114. | 4.5 | 26 |
| 71 | Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. PLoS ONE, 2017, 12, e0168834. | 2.5 | 25 |
| 72 | Longitudinal follow-up of vision in a neuromyelitis optica cohort. Multiple Sclerosis Journal, 2013, 19, 1320-1322. | 3.0 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study. PLoS ONE, 2017, 12, e0188120. | 2.5 | 24 |
| 74 | Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome. Revue Neurologique, 2015, 171, 390-393. | 1.5 | 23 |
| 75 | New insights into the burden and costs of multiple sclerosis in Europe: Results for France. Multiple Sclerosis Journal, 2017, 23, 65-77. | 3.0 | 23 |
| 76 | Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731983666. | 1.0 | 23 |
| 77 | Pregnancy with multiple sclerosis. Revue Neurologique, 2021, 177, 180-194. | 1.5 | 23 |
| 78 | Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. Current Opinion in Neurology, 2021, 34, 322-328. | 3.6 | 23 |
| 79 | From the prodromal stage of multiple sclerosis to disease prevention. Nature Reviews Neurology, 2022, 18, 559-572. | 10.1 | 23 |
| 80 | A Prospective Study of Patients with Brain MRI Showing Incidental T2 Hyperintensities Addressed as Multiple Sclerosis: a Lot of Work to do Before Treating. Neurology and Therapy, 2014, 3, 123-132. | 3.2 | 22 |
| 81 | Evolution of Nevi During Treatment With Natalizumab. Archives of Dermatology, 2010, 147, 72. | 1.4 | 21 |
| 82 | EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis. Journal of Neuro-Oncology, 2011, 102, 171-178. | 2.9 | 21 |
| 83 | The radiologically isolated syndrome. Revue Neurologique, 2015, 171, 698-706. | 1.5 | 21 |
| 84 | Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease. Multiple Sclerosis Journal, 2014, 20, 1135-1139. | 3.0 | 20 |
| 85 | Evaluation of quality of life and fatigue in radiologically isolated syndrome. Revue Neurologique, 2016, 172, 392-395. | 1.5 | 20 |
| 86 | A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication. Journal of NeuroVirology, 2017, 23, 216-225. | 2.1 | 19 |
| 87 | CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. Neurology, 2016, 87, 2491-2494. | 1.1 | 18 |
| 88 | Cerebellar volume loss in radiologically isolated syndrome. Multiple Sclerosis Journal, 2021, 27, 130-133. | 3.0 | 18 |
| 89 | Turcot syndrome confirmed with molecular analysis. European Journal of Neurology, 2007, 14, 470-472. | 3.3 | 17 |
| 90 | Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders. Journal of the Neurological Sciences, 2016, 368, 334-336. | 0.6 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Disorders (HAND). Heliyon, 2017, 3, e00245. | 3.2 | 17 |
| 92 | Association of Immunosuppression and Viral Load With Subcortical Brain Volume in an International Sample of People Living With HIV. JAMA Network Open, 2021, 4, e2031190. | 5.9 | 16 |
| 93 | The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456. | 3.0 | 16 |
| 94 | Anomalies Characteristic of Central Nervous System Demyelination. Neurologic Clinics, 2018, 36, 59-68. | 1.8 | 15 |
| 95 | Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Revue Neurologique, 2019, 175, 341-357. | 1.5 | 15 |
| 96 | Matrix metalloproteinase 9 is decreased in natalizumabâ€treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. Annals of Neurology, 2017, 82, 186-195. | 5.3 | 14 |
| 97 | Cerebrospinal Fluid IL-17A Could Predict Acute Disease Severity in Non-NMDA-Receptor Autoimmune Encephalitis. Frontiers in Immunology, 2021, 12, 673021. | 4.8 | 14 |
| 98 | Risk for Nevus Transformation and Melanoma Proliferation and Invasion During Natalizumab Treatment. JAMA Dermatology, 2014, 150, 901. | 4.1 | 13 |
| 99 | False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients. Multiple Sclerosis Journal, 2016, 22, 1231-1234. | 3.0 | 13 |
| 100 | Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals. Neurology, 2019, 93, 550-554. | 1.1 | 13 |
| 101 | Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis Journal, 2019, 25, 591-600. | 3.0 | 13 |
| 102 | Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies. Journal of Neuroinflammation, 2020, 17, 128. | 7.2 | 13 |
| 103 | Hemophagocytic Lymphohistiocytosis Gene Mutations in Adult Patients Presenting With CLIPPERS-Like Syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, . | 6.0 | 13 |
| 104 | How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). Multiple Sclerosis and Related Disorders, 2021, 53, 103076. | 2.0 | 13 |
| 105 | Progressive spastic paraparesis revealing primary hyperparathyroidism. Neurology, 1994, 44, 178-178. | 1.1 | 13 |
| 106 | Cutaneous Side-effects of Immunomodulators in MS. International MS Journal, 2011, 17, 88-94. | 0.3 | 13 |
| 107 | A longitudinal observational study of a cohort of patients with relapsingâ€“remitting multiple sclerosis treated with glatiramer acetate. European Journal of Neurology, 2007, 14, 1266-1274. | 3.3 | 12 |
| 108 | Natalizumab-PML survivors with subsequent MS treatment. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e346. | 6.0 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | A Case Report of Solitary Sclerosis: This is Really Multiple Sclerosis. Neurology and Therapy, 2017, 6, 259-263. | 3.2 | 12 |
| 110 | Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, . | 6.0 | 12 |
| 111 | Leukoencephalopathy in multiple myeloma: Two case reports. Annals of Oncology, 1999, 10, 1515-1517. | 1.2 | 11 |
| 112 | Solitary sclerosis: Experience from three French tertiary care centres. Multiple Sclerosis Journal, 2015, 21, 1216-1216. | 3.0 | 11 |
| 113 | Solitary meningeal plasmacytomas. Annals of Oncology, 1997, 8, 791-795. | 1.2 | 10 |
| 114 | Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study. Multiple Sclerosis and Related Disorders, 2016, 6, 93-96. | 2.0 | 10 |
| 115 | Gender Inequities in the Multiple Sclerosis Community: A Call for Action. Annals of Neurology, 2018, 84, 958-959. | 5.3 | 10 |
| 116 | CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, . | 6.0 | 10 |
| 117 | GIANT URTICARIA AND PERSISTENT NEUTRALIZING ANTIBODIES AFTER THE FIRST NATALIZUMAB INFUSION. Neurology, 2010, 74, 1394-1395. | 1.1 | 9 |
| 118 | Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time: Yes. Multiple Sclerosis Journal, 2012, 18, 1531-1532. | 3.0 | 9 |
| 119 | Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. Multiple Sclerosis and Related Disorders, 2019, 28, 109-116. | 2.0 | 9 |
| 120 | BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. Multiple Sclerosis Journal, 2021, 27, 1556-1563. | 3.0 | 9 |
| 121 | Covid-19, the pandemic war: Implication for neurologists. Revue Neurologique, 2020, 176, 223-224. | 1.5 | 9 |
| 122 | Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis. Neurotherapeutics, 2021, 18, 938-948. | 4.4 | 9 |
| 123 | Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?. Multiple Sclerosis Journal, 2021, 27, 2280-2283. | 3.0 | 9 |
| 124 | Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France. Journal of Neurology, 2019, 266, 888-901. | 3.6 | 8 |
| 125 | Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. Multiple Sclerosis Journal, 2021, 27, 1458-1463. | 3.0 | 8 |
| 126 | Video-oculography in multiple sclerosis: Links between oculomotor disorders and brain magnetic resonance imaging (MRI). Multiple Sclerosis and Related Disorders, 2020, 40, 101969. | 2.0 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Untreated patients with multiple sclerosis: A study of French expert centers. European Journal of Neurology, 2021, 28, 2026-2036. | 3.3 | 8 |
| 128 | The effectiveness of natalizumab vs fingolimodâ€"A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012. | 2.0 | 8 |
| 129 | Recurrent bowel occlusion with oral ondansetron with no side effects of the intravenous route: A previously unknown adverse event. Annals of Oncology, 1997, 8, 919-920. | 1.2 | 7 |
| 130 | Endermology: A treatment for injection-induced lipoatrophy in multiple sclerosis patients treated with sub cutaneous glatiramer acetate. Clinical Neurology and Neurosurgery, 2011, 113, 721-724. | 1.4 | 7 |
| 131 | Multiple immune disorders after natalizumab discontinuation: After the CIRIS, the SIRIS?. Revue Neurologique, 2017, 173, 222-224. | 1.5 | 7 |
| 132 | Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment. Neurology and Therapy, 2020, 9, 599-604. | 3.2 | 7 |
| 133 | Alexithymia in multiple sclerosis: Clinical and radiological correlations. Revue Neurologique, 2021, 177, 302-311. | 1.5 | 7 |
| 134 | The HV3 Score: A New Simple Tool to Suspect Cognitive Impairment in Multiple Sclerosis in Clinical Practice. Neurology and Therapy, 2014, 3, 113-122. | 3.2 | 6 |
| 135 | Demonstration of a lexical access deficit in relapsing-remitting and secondary progressive forms of multiple sclerosis. Revue Neurologique, 2014, 170, 527-530. | 1.5 | 6 |
| 136 | Radiologically isolated syndrome should be treated with disease-modifying therapy â€" Commentary. Multiple Sclerosis Journal, 2017, 23, 1821-1823. | 3.0 | 6 |
| 137 | Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France. Multiple Sclerosis Journal, 2008, 14, 933-939. | 3.0 | 5 |
| 138 | RECURRENT PERICARDITIS DUE TO NATALIZUMAB TREATMENT. Neurology, 2009, 72, 1616-1617. | 1.1 | 5 |
| 139 | Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2021, 27, 232-238. | 3.0 | 5 |
| 140 | Digital biomarkers can highlight subtle clinical differences in radiologically isolated syndrome compared to healthy controls. Journal of Neurology, 2021, 268, 1316-1322. | 3.6 | 5 |
| 141 | Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis. Neurotherapeutics, 2021, 18, 378-386. | 4.4 | 5 |
| 142 | The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients â€" No. Multiple Sclerosis Journal, 2021, 27, 1824-1826. | 3.0 | 5 |
| 143 | Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsingâ€"Remitting Multiple Sclerosis After Fingolimod Withdrawal. Neurotherapeutics, 2022, 19, 476-490. | 4.4 | 5 |
| 144 | Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities. Frontiers in Immunology, 2022, 13, 864133. | 4.8 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year. Journal of the Neurological Sciences, 2017, 382, 73-78. | 0.6 | 4 |
| 146 | Impact of executive dysfunction on naming ability in multiple sclerosis. Revue Neurologique, 2019, 175, 552-559. | 1.5 | 4 |
| 147 | De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine. Multiple Sclerosis Journal, 2019, 25, 618-621. | 3.0 | 4 |
| 148 | Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?. Multiple Sclerosis and Related Disorders, 2017, 18, 161-163. | 2.0 | 3 |
| 149 | Digestive side-effects with teriflunomide: Thoughts on lactose. Revue Neurologique, 2018, 174, 722-725. | 1.5 | 3 |
| 150 | Bevacizumab: Is the lower the better for glioblastoma patients in progression?. Bulletin Du Cancer, 2018, 105, 1135-1146. | 1.6 | 3 |
| 151 | Validation of a rapid and easy-to-perform screening test for neurocognitive impairment in HIV+ patients. Journal of the Neurological Sciences, 2020, 410, 116664. | 0.6 | 3 |
| 152 | Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851. | 3.0 | 3 |
| 153 | Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study. Neurology and Therapy, 2022, 11, 633-658. | 3.2 | 3 |
| 154 | Moving to Fingolimod From Natalizumab in Multiple Sclerosisâ€"Reply. JAMA Neurology, 2014, 71, 925. | 9.0 | 2 |
| 155 | Should we treat patients with radiologically isolated syndrome (RIS)? Comments. Revue Neurologique, 2018, 174, 696-698. | 1.5 | 2 |
| 156 | Carnitine serum levels and levocarnitine administration in multiple sclerosis patients treated with natalizumab. European Journal of Neurology, 2011, 18, e63-e64. | 3.3 | 1 |
| 157 | Investigating the Effect of Teriflunomide on Diffuse Brain Tissue Damage in the Phase 3 TEMSO Study. Multiple Sclerosis and Related Disorders, 2018, 26, 258-259. | 2.0 | 1 |
| 158 | MRI findings in blinded trials should be available to treating physicians â€“ Yes. Multiple Sclerosis Journal, 2021, 27, 812-813. | 3.0 | 1 |
| 159 | Les syndromes radiologiquement isolÃ©s. Neurologie Com, 2010, 2, 139-141. | 0.0 | 0 |
| 160 | Les traitements de premiÃ¨re ligne dans la sclÃ©rose en plaques. Pratique Neurologique - FMC, 2012, 3, 73-89. | 0.1 | 0 |
| 161 | Uncommon foreign body reaction caused by derivation drain mimicking high grade CNS tumor. Journal of the Neurological Sciences, 2014, 340, 237-238. | 0.6 | 0 |
| 162 | Country break-out session highlights. Neurodegenerative Disease Management, 2015, 5, 31-37. | 2.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Multiple sclerosis treatments and the anti-JCV antibody index. Revue Neurologique, 2017, 173, e1. | 1.5 | 0 |
| 164 | Hypertension intracrÃ¢nienne idiopathique dans le cadre dâ€™une obÃ©sitÃ© ou dâ€™un surpoids : Ã©tude observationnelle. Diabetes and Metabolism, 2017, 43, A100. | 2.9 | 0 |
| 165 | Signes et symptÃ´mes de la sclÃ©rose en plaques. , 2017, , 3-78. | | 0 |
| 166 | Demyelinating diseases. Revue Neurologique, 2018, 174, 355. | 1.5 | 0 |
| 167 | Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial. Revue Neurologique, 2021, , . | 1.5 | 0 |
| 168 | Association of cancer and stroke: A population-based study. Journal of Clinical Oncology, 2008, 26, 20672-20672. | 1.6 | 0 |
| 169 | Diagnostic positif de la sclÃ©rose en plaques. , 2017, , 79-111. | | 0 |
| 170 | Common Brain Volume Signatures Associated with Immunosuppression and Viral Load in Over 1000 Adults Living with HIV Across 5 Continents: Findings from the ENIGMA-HIV Working Group. SSRN Electronic Journal, 0, , . | 0.4 | 0 |